|
Canada-ON-CALEDON EAST Azienda Directories
|
Azienda News:
- Dual Antiplatelet Therapy Versus Aspirin in Patients With . . .
Graphical Abstract Background and Purpose: Antiplatelet therapy is key for preventing thrombotic events after transient ischemic attack or ischemic stroke Although the role of aspirin is well established, there is emerging evidence for the role of short-term dual antiplatelet therapy (DAPT) in preventing recurrent stroke Methods: We conducted a systematic review and study-level meta-analyses
- Clopidogrel with aspirin in High-risk patients with Acute Non . . .
svn-2020-000791supp001 pdf (71 7KB, pdf) Secondary outcomes Secondary outcomes include the following events: (1) Any new stroke events within 30 days and 1 year; (2) New clinical vascular events including stroke, TIA, myocardial infarction and vascular deaths within 3 months and 1 year; (3) New ischaemic stroke within 3 months and 1 year; (4) Disabling stroke (Modified Rankin Scale score
- Comparison of Dual Antiplatelet Therapies for Nondisabling . . .
Source Trial name Cohort years NIHSS range Time to randomization, h Treatment a Aspirin, mg a DAPT, mg Treatment duration, d; Loading Maintenance Loading Maintenance
- CHANCE trial: early short-term dual antiplatelet treatment . . .
CHANCE trial: early short-term dual antiplatelet treatment for stroke prevention
- Dual antiplatelet therapy in stroke and ICAS: Subgroup . . .
The results indicated higher rate of recurrent stroke in minor stroke or high-risk TIA patients with ICAS than in those without However, there was no significant difference in the response to the 2 antiplatelet therapies between patients with and without ICAS in the CHANCE trial Classification of …
- Clopidogrel with Aspirin in Acute Minor Stroke or Transient . . .
Clopidogrel with Aspirin in Stroke or TIA n engl j med 369;1 nejm org july 4, 2013 13 other conditions, such as vascular malformation, tumor, abscess, or other major nonischemic brain
- Ticagrelor Aspirin vs Clopidogrel Aspirin in CYP2C19 Loss-of . . .
Genotype data of the Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) trial showed that efficacy of clopidogrel aspirin depended on CYP2C19 genotype and risk profile A stratification of patients who carried
|
|